Advances in Clinical and Experimental Medicine,
Год журнала:
2022,
Номер
31(5), С. 469 - 473
Опубликована: Май 12, 2022
Population
aging
that
we
are
currently
witnessing
has
led
to
an
increase
in
chronic
age-related
diseases,
with
dementia
and
depression
being
highlighted.Several
studies
establish
a
relationship
between
depression,
although
without
defining
the
mechanism
links
them.Some
as
prodrome
of
dementia,
while
others
consider
it
risk
factor
for
dementia.One
events
is
common
inflammatory
process.In
cytokines
been
described,
which
would
justify
serotonergic,
noradrenergic
dopaminergic
dysfunction
depression.This
entails
altering
activity
hypothalamic-pituitary-adrenal
(HPA)
axis,
thus
linking
stress
consequent
weakening
blood-brain
barrier
(BBB),
facilitating
passage
pro-inflammatory
factors.In
this
line,
recent
suggest
inflammation
could
direct
development
pathogenesis
particularly
Alzheimer's
disease
(AD),
once
pathology
begun.In
addition,
sustained
exposure
characteristic
alter
microglial
function
expression
enzymes
responsible
amyloid
peptide
metabolism,
aggravating
pathological
view
involvement
process
both
conditions,
necessary
investigate
conditions
share,
such
process,
know
possible
these
2
consequently,
clinical
approach
conditions.
Cells,
Год журнала:
2023,
Номер
12(22), С. 2649 - 2649
Опубликована: Ноя. 17, 2023
Migraine
is
a
neurovascular
disorder
that
can
be
debilitating
for
individuals
and
society.
Current
research
focuses
on
finding
effective
analgesics
management
strategies
migraines
by
targeting
specific
receptors
neuropeptides.
Nonetheless,
newly
approved
calcitonin
gene-related
peptide
(CGRP)
monoclonal
antibodies
(mAbs)
have
50%
responder
rate
ranging
from
27
to
71.0%,
whereas
CGRP
receptor
inhibitors
56
71%.
To
address
the
need
novel
therapeutic
targets,
researchers
are
exploring
potential
of
another
secretin
family
peptide,
pituitary
adenylate
cyclase-activating
polypeptide
(PACAP),
as
ground-breaking
treatment
avenue
migraine.
Preclinical
models
revealed
how
PACAP
affects
trigeminal
system,
which
implicated
in
headache
disorders.
Clinical
studies
demonstrated
significance
migraine
pathophysiology;
however,
few
clinical
trials
remain
inconclusive:
1
mAb,
AMG
301
showed
no
benefit
prevention,
while
ligand
Lu
AG09222
significantly
reduced
number
monthly
days
over
placebo
phase
2
trial.
Meanwhile,
vasoactive
intestinal
(VIP)
gaining
interest
new
target.
In
light
recent
advances
research,
we
emphasize
promising
target
treatment,
highlighting
member
antimigraine
armamentarium,
especially
patients
who
do
not
respond
or
contraindicated
anti-CGRP
therapies.
By
updating
our
knowledge
its
unique
contribution
pathophysiology,
pave
way
reinforcing
other
peptides,
including
VIP,
option
migraines.
